Investors

Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$0.76 - 0.02 (2.56%)
Day High:$0.82
Day Low:$0.75
Volume:289,676
07/19/194:00 p.m. ET
Delayed at least 15 minutes.

Maeve Conneighton
Ph +1-212-600-1902
CTI@argotpartners.com


 

Recent News

MORE
DateTitle 
Jul 18, 2019CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
- Company Plans to Advance Pacritinib 200 mg Twice-Daily (BID) Dose to Phase 3 for Patients With Severe Thrombocytopenia - - Company Plans to Initiate PACIFICA Phase 3 Trial in Third Quarter of 2019 - SEATTLE, July 18, 2019 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI" or "the Company") today announced the outcome of a Type B, End-of-Phase-2a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency") for the continued development of its investigational myelofi... 
Printer Friendly Version
Jun 13, 2019CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
SEATTLE, June 13, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City. Presentation details: Event: JMP Securities Life Sciences Conference Date: Thursday, Jun. 20 Time: ... 
Printer Friendly Version
May 29, 2019CTI BioPharma to Present at the Jefferies Global Healthcare Conference on Wednesday, Jun. 5
SEATTLE, May 29, 2019 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies Global Healthcare Conference at 4:30 p.m. EDT in New York City. Presentation details: Event: Jefferies Global Healthcare Conference Date: Wednesday, Jun. 5 Time: ... 
Printer Friendly Version

Events

MORE
There are currently no events scheduled.

Presentation

DateTitle
June 2019
Download Documentation CTI BioPharma Corporate Presentation
Get help downloading or viewing the above file types
Data provided by Nasdaq. Minimum 15 minutes delayed.